U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C7H8N4O2.C7H4O3.Ca
Molecular Weight 356.3475
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of THEOPHYLLINE CALCIUM SALICYLATE

SMILES

Cn1c2c(c(=O)n(C)c1=O)nc[nH]2.c1ccc(c(c1)C(=O)[O-])[O-].[Ca+2]

InChI

InChIKey=HBGYWKVYHHULPL-UHFFFAOYSA-L
InChI=1S/C7H8N4O2.C7H6O3.Ca/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13;8-6-4-2-1-3-5(6)7(9)10;/h3H,1-2H3,(H,8,9);1-4,8H,(H,9,10);/q;;+2/p-2

HIDE SMILES / InChI

Molecular Formula Ca
Molecular Weight 40.078
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C7H4O3
Molecular Weight 136.1051
Charge -2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C7H8N4O2
Molecular Weight 180.1643
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: https://www.ncbi.nlm.nih.gov/pubmed/9676340 | https://www.ncbi.nlm.nih.gov/pubmed/27713276

Theophylline is indicated for the treatment of acute exacerbations of the symptoms and reversible airflow obstruction associated with asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.

Originator

Curator's Comment:: Albert Kossel discovered theophylline as a component of the tea leaf

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

Approved Use

Theophylline is indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.

Launch Date

396489600000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7.3 μg/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
THEOPHYLLINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
95.5 μg × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
THEOPHYLLINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8.51 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
THEOPHYLLINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
41%
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
THEOPHYLLINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
20 mg/mL steady, intravenous
Highest studied dose
Dose: 20 mg/mL
Route: intravenous
Route: steady
Dose: 20 mg/mL
Sources:
unhealthy, 39 years (51 % < 40 years)
Health Status: unhealthy
Age Group: 39 years (51 % < 40 years)
Sex: M+F
Sources:
Disc. AE: Vomiting...
Other AEs: Vomiting...
AEs leading to
discontinuation/dose reduction:
Vomiting (grade 3, 5.75%)
Other AEs:
Vomiting (12.64%)
Sources:
1200 mg 1 times / day steady, oral
Recommended
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources:
unhealthy, 66 ± 9
Health Status: unhealthy
Age Group: 66 ± 9
Sex: M+F
Sources:
Disc. AE: Gastrointestinal discomfort, Supraventricular tachycardia...
Other AEs: Tremor, Nervousness...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal discomfort (grade 3, 16.7%)
Supraventricular tachycardia (grade 3, 16.7%)
Other AEs:
Tremor (16.7%)
Nervousness (16.7%)
Dysrhythmias (grade 1, 16.7%)
Sources:
800 mg single, oral
Recommended
Dose: 800 mg
Route: oral
Route: single
Dose: 800 mg
Sources:
unhealthy, 66 ± 9
Health Status: unhealthy
Age Group: 66 ± 9
Sex: M
Sources:
800 mg 1 times / day steady, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: steady
Dose: 800 mg, 1 times / day
Sources:
unhealthy, 66 ± 9
Health Status: unhealthy
Age Group: 66 ± 9
Sex: M+F
Sources:
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Other AEs: Vomiting, Hypokalemia...
Other AEs:
Vomiting (30%)
Hypokalemia (44%)
Hyperglycemia (18%)
Acid-base balance abnoraml (9%)
Sinus tachycardia (100%)
Supraventricular tachycardia (12%)
Premature ventricular ectopic beats (10%)
Atrial flutter/ fibrillation (12%)
Multifocal atrial tachycardia (2%)
Hemodynamic instability (40%)
Tremor (16%)
Seizures (14%)
Sources:
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Other AEs: Vomiting, Abdominal pain...
Other AEs:
Vomiting (61%)
Abdominal pain (12%)
Diarrhea (14%)
Hematemesis (2%)
Hypokalemia (43%)
Acid-base balance abnoraml (9%)
Sinus tachycardia (62%)
Supraventricular tachycardia (14%)
Premature ventricular ectopic beats (19%)
Hypotension (8%)
Nervousness (21%)
Tremor (14%)
Disorientation (11%)
Seizures (5%)
Sources:
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Other AEs: Generalized epileptic seizure, Cardiac arrhythmias...
Other AEs:
Generalized epileptic seizure (grade 4-5)
Cardiac arrhythmias (grade 4-5)
Calcium increased serum
Creatine kinase increased
Blood myoglobin increased
Leukocyte count increased
Serum phosphate decreased
Magnesium serum decreased
Acute myocardial infarction
Obstructive uropathy
Cardio-respiratory arrest (grade 5)
Hypoxic encephalopathy (grade 5)
Sources:
10 mg/kg single, oral
Overdose
unknown
Other AEs: Abdominal pain, Rhabdomyolysis...
Other AEs:
Abdominal pain (21%)
Rhabdomyolysis (7%)
Hypotension (21%)
Nervousness (64%)
Disorientation (7%)
Sources:
10 mg/kg single, oral
Overdose
unknown
Other AEs: Vomiting, Hypokalemia...
Other AEs:
Vomiting (73%)
Hypokalemia (85%)
Hyperglycemia (98%)
Acid-base balance abnoraml (34%)
Sinus tachycardia (100%)
Supraventricular tachycardia (2%)
Premature ventricular ectopic beats (3%)
Atrial flutter/ fibrillation (1%)
Hemodynamic instability (7%)
Tremor (38%)
Seizures (5%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Vomiting 12.64%
20 mg/mL steady, intravenous
Highest studied dose
Dose: 20 mg/mL
Route: intravenous
Route: steady
Dose: 20 mg/mL
Sources:
unhealthy, 39 years (51 % < 40 years)
Health Status: unhealthy
Age Group: 39 years (51 % < 40 years)
Sex: M+F
Sources:
Vomiting grade 3, 5.75%
Disc. AE
20 mg/mL steady, intravenous
Highest studied dose
Dose: 20 mg/mL
Route: intravenous
Route: steady
Dose: 20 mg/mL
Sources:
unhealthy, 39 years (51 % < 40 years)
Health Status: unhealthy
Age Group: 39 years (51 % < 40 years)
Sex: M+F
Sources:
Nervousness 16.7%
1200 mg 1 times / day steady, oral
Recommended
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources:
unhealthy, 66 ± 9
Health Status: unhealthy
Age Group: 66 ± 9
Sex: M+F
Sources:
Tremor 16.7%
1200 mg 1 times / day steady, oral
Recommended
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources:
unhealthy, 66 ± 9
Health Status: unhealthy
Age Group: 66 ± 9
Sex: M+F
Sources:
Dysrhythmias grade 1, 16.7%
1200 mg 1 times / day steady, oral
Recommended
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources:
unhealthy, 66 ± 9
Health Status: unhealthy
Age Group: 66 ± 9
Sex: M+F
Sources:
Gastrointestinal discomfort grade 3, 16.7%
Disc. AE
1200 mg 1 times / day steady, oral
Recommended
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources:
unhealthy, 66 ± 9
Health Status: unhealthy
Age Group: 66 ± 9
Sex: M+F
Sources:
Supraventricular tachycardia grade 3, 16.7%
Disc. AE
1200 mg 1 times / day steady, oral
Recommended
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources:
unhealthy, 66 ± 9
Health Status: unhealthy
Age Group: 66 ± 9
Sex: M+F
Sources:
Premature ventricular ectopic beats 10%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Sinus tachycardia 100%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Atrial flutter/ fibrillation 12%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Supraventricular tachycardia 12%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Seizures 14%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Tremor 16%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Hyperglycemia 18%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Multifocal atrial tachycardia 2%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Vomiting 30%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Hemodynamic instability 40%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Hypokalemia 44%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Acid-base balance abnoraml 9%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Disorientation 11%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Abdominal pain 12%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Diarrhea 14%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Supraventricular tachycardia 14%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Tremor 14%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Premature ventricular ectopic beats 19%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Hematemesis 2%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Nervousness 21%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Hypokalemia 43%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Seizures 5%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Vomiting 61%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Sinus tachycardia 62%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Hypotension 8%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Acid-base balance abnoraml 9%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Acute myocardial infarction
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Blood myoglobin increased
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Calcium increased serum
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Creatine kinase increased
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Leukocyte count increased
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Magnesium serum decreased
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Obstructive uropathy
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Serum phosphate decreased
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Cardiac arrhythmias grade 4-5
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Generalized epileptic seizure grade 4-5
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Cardio-respiratory arrest grade 5
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Hypoxic encephalopathy grade 5
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Abdominal pain 21%
10 mg/kg single, oral
Overdose
unknown
Hypotension 21%
10 mg/kg single, oral
Overdose
unknown
Nervousness 64%
10 mg/kg single, oral
Overdose
unknown
Disorientation 7%
10 mg/kg single, oral
Overdose
unknown
Rhabdomyolysis 7%
10 mg/kg single, oral
Overdose
unknown
Atrial flutter/ fibrillation 1%
10 mg/kg single, oral
Overdose
unknown
Sinus tachycardia 100%
10 mg/kg single, oral
Overdose
unknown
Supraventricular tachycardia 2%
10 mg/kg single, oral
Overdose
unknown
Premature ventricular ectopic beats 3%
10 mg/kg single, oral
Overdose
unknown
Acid-base balance abnoraml 34%
10 mg/kg single, oral
Overdose
unknown
Tremor 38%
10 mg/kg single, oral
Overdose
unknown
Seizures 5%
10 mg/kg single, oral
Overdose
unknown
Hemodynamic instability 7%
10 mg/kg single, oral
Overdose
unknown
Vomiting 73%
10 mg/kg single, oral
Overdose
unknown
Hypokalemia 85%
10 mg/kg single, oral
Overdose
unknown
Hyperglycemia 98%
10 mg/kg single, oral
Overdose
unknown
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Computerised advice on drug dosage to improve prescribing practice.
2001
Oral methyl-xanthines for bronchiectasis.
2001
Methyl-xanthines for exacerbations of chronic obstructive pulmonary disease.
2001
Treatment options for sleep apnoea.
2001
Doxofylline: a new generation xanthine bronchodilator devoid of major cardiovascular adverse effects.
2001
Time dependence of elastic recovery for characterization of tableting materials.
2001
A comparison of reflectance and transmittance near-infrared spectroscopic techniques in determining drug content in intact tablets.
2001
A novel method for measuring gel strength of controlled release hydrogel tablets using a cone/plate rheometer.
2001
Caffeine citrate: a review of its use in apnoea of prematurity.
2001
Creatinine clearance overestimated glomerular filtration rate in a heavy tea-drinker.
2001 Apr
Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin.
2001 Apr
Antiasthmatic effect of YM976, a novel PDE4 inhibitor, in guinea pigs.
2001 Apr
Preparation of controlled release systems by free-radical UV polymerizations in the presence of a drug.
2001 Apr 2
How to safeguard delivery of high-alert i.v. drugs.
2001 Feb
Caffeine metabolism before and after liver transplantation.
2001 Feb
Metabolism of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline in human hepatocytes: 2-amino-3-methylimidazo[4,5-f]quinoxaline-8-carboxylic acid is a major detoxification pathway catalyzed by cytochrome P450 1A2.
2001 Feb
High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. V. Validation of a direct injection/on-line guard cartridge extraction--tandem mass spectrometry method for CYP1A2 inhibition assessment.
2001 Feb
Myocardial perfusion imaging findings and the role of adenosine in the warm-up angina phenomenon.
2001 Feb
Theophylline metabolism after cardiac surgery.
2001 Feb
Effect of coadministered drugs and ethanol on the binding of therapeutic drugs to human serum in vitro.
2001 Feb
Advair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthma.
2001 Feb
[Use of the paraxanthine/caffeine ratio in the saliva of patients with liver cirrhosis].
2001 Feb 1
Determination of urinary methylated purine pattern by high-performance liquid chromatography.
2001 Feb 10
Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells.
2001 Feb 15
Hepatic arteriolo-portal venular shunting guarantees maintenance of nutritional microvascular supply in hepatic arterial buffer response of rat livers.
2001 Feb 15
Role of adenosine and glycogen in ischemic preconditioning of rat hearts.
2001 Feb 23
[Cerebral infarction in a patient consuming MaHuang extract and guarana].
2001 Feb 3
Development of heart failure in bradycardic sick sinus syndrome.
2001 Jan
Caffeine metabolism in a group of 67 patients with primary biliary cirrhosis.
2001 Jan
Clinical correlations in infants in the neonatal intensive care unit with varying severity of gastroesophageal reflux.
2001 Jan
Suspected caffeine and ephedrine toxicosis resulting from ingestion of an herbal supplement containing guarana and ma huang in dogs: 47 cases (1997-1999).
2001 Jan 15
Severe hyponatremia induced by theophylline and trimethoprim.
2001 Jan 22
Newer and alternative non-steroidal treatments for asthmatic inflammation.
2001 Jan-Feb
Improvement of encapsulation efficiency of water-in-oil-in-water emulsion with hypertonic inner aqueous phase.
2001 Jan-Feb
Adenosine diphosphate ribose dilates bovine coronary small arteries through apyrase- and 5'-nucleotidase-mediated metabolism.
2001 Jan-Feb
The mechanism of gentisic acid-induced relaxation of the guinea pig isolated trachea: the role of potassium channels and vasoactive intestinal peptide receptors.
2001 Mar
Drug treatment of airway inflammation in asthma.
2001 Mar
Plasma adenosine levels and P-selectin expression on platelets in preeclampsia.
2001 Mar
Adenosine inhibits norepinephrine release in the postischemic rat heart: the mechanism of neuronal stunning.
2001 Mar
Antiarrhythmic effects of adenosine on ischemia-induced ventricular fibrillation.
2001 Mar
Study of in vitro and in vivo dissolution of theophylline from film-coated pellets.
2001 Mar
New combination therapies for asthma.
2001 Mar
Refractory seizure with hypokalaemia.
2001 Mar
Continuous venovenous haemofiltration for the treatment of theophylline toxicity.
2001 Mar
Profile of moxifloxacin drug interactions.
2001 Mar 15
A multiparticulate drug-delivery system based on pellets incorporated into congealable polyethylene glycol carrier materials.
2001 Mar 23
Activation of glutamate uptake by guanosine in primary astrocyte cultures.
2001 Mar 26
Inhibitory effect of theophylline on recombinant GABA(A) receptor.
2001 Mar 5
Cytosolic xanthine oxidoreductase mediated bioactivation of ethanol to acetaldehyde and free radicals in rat breast tissue. Its potential role in alcohol-promoted mammary cancer.
2001 Mar 7
Escape deficits induced by inescapable shock and metabolic stress are reversed by adenosine receptor antagonists.
2001 May
Patents

Sample Use Guides

For a given population there is no single theophylline dose that will provide both safe
Route of Administration: Other
1 mM theophylline inhibited histamine release from human skin mast cells
Substance Class Chemical
Created
by admin
on Sat Jun 26 12:12:46 UTC 2021
Edited
by admin
on Sat Jun 26 12:12:46 UTC 2021
Record UNII
VWZ980637N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
THEOPHYLLINE CALCIUM SALICYLATE
VANDF   WHO-DD  
Systematic Name English
BENZOIC ACID, 2-HYDROXY-, COMPD. WITH 3,9-DIHYDRO-1,3-DIMETHYL-1H-PURINE-2,6-DIONE, CALCIUM SALT (1:1:1)
Common Name English
SALICYLIC ACID, CALCIUM SALT (1:1), COMPD. WITH THEOPHYLLINE (1:1)
Common Name English
THEOPHYLLINE CALCIUM SALICYLATE [WHO-DD]
Common Name English
THEOPHYLLINE CALCIUM SALICYLATE [VANDF]
Common Name English
Code System Code Type Description
CAS
129-98-6
Created by admin on Sat Jun 26 12:12:46 UTC 2021 , Edited by admin on Sat Jun 26 12:12:46 UTC 2021
PRIMARY
PUBCHEM
9841621
Created by admin on Sat Jun 26 12:12:46 UTC 2021 , Edited by admin on Sat Jun 26 12:12:46 UTC 2021
PRIMARY
EVMPD
SUB15518MIG
Created by admin on Sat Jun 26 12:12:46 UTC 2021 , Edited by admin on Sat Jun 26 12:12:46 UTC 2021
PRIMARY
FDA UNII
VWZ980637N
Created by admin on Sat Jun 26 12:12:46 UTC 2021 , Edited by admin on Sat Jun 26 12:12:46 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY